Skip to main content
Addgene

Enter a sequence to perform a BLAST-based search of the Addgene plasmid sequence database.

Information

In Category

Filter By

We narrowed to 147 results for: ef1a

Showing: 101 - 120 of 147 results

  1. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV5)

    Viral Prep
    #26966-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.
    Promoter
    EF1a
    Tags
    EYFP (Cre-dependent)
    Available since
    Feb. 14, 2018
    Availability
    Academic Institutions and Nonprofits only

  2. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV9)

    Viral Prep
    #26966-AAV9
    Purpose
    Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.
    Promoter
    EF1a
    Tags
    EYFP (Cre-dependent)
    Available since
    April 6, 2018
    Availability
    Academic Institutions and Nonprofits only

  3. pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE (AAV1)

    Viral Prep
    #130998-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE (#130998). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of ChRmine-mScarlet. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Marshel et al Science. 2019 Aug 9;365(6453). pii: scie
    Promoter
    EF1a
    Tags
    mScarlet
    Available since
    Sept. 27, 2024
    Availability
    Academic Institutions and Nonprofits only

  4. pAAV-Ef1a-DIO C1V1 (t/t)-TS-mCherry (PV2670) (AAV9)

    Viral Prep
    #100061-AAV9
    Purpose
    Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO C1V1 (t/t)-TS-mCherry (PV2670) (#100061). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO C1V1 (t/t)-TS-mCherry (PV2670) plasmid DNA. EFIa-driven, Cre-dependent, C1V1 (t/t) fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Promoter
    EF1a
    Tags
    mCherry (Cre-dependent)
    Available since
    April 6, 2018
    Availability
    Academic Institutions and Nonprofits only

  5. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV1)

    Viral Prep
    #87306-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Li Zhang
    Article
    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.
    Promoter
    EF1a
    Tags
    None
    Available since
    April 18, 2019
    Availability
    Academic Institutions and Nonprofits only

  6. pAAV-Ef1a-Con/Foff 2.0-sRGECO (AAV8)

    Viral Prep
    #137127-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-sRGECO (#137127). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-sRGECO plasmid DNA. EF1a-driven, Cre-dependent expression of cytosolic sRGECO calcium sensor (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth, INTRSECT 2.0 Project
    Article
    Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)
    Promoter
    EF1a
    Tags
    None
    Available since
    May 18, 2021
    Availability
    Academic Institutions and Nonprofits only

  7. pAAV-Ef1a-Con/Foff 2.0-GCaMP6F (AAV8)

    Viral Prep
    #137123-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6F (#137123). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6F plasmid DNA. EF1a-driven, Cre-dependent expression of GCaMP6f (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth, INTRSECT 2.0 Project
    Article
    Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)
    Promoter
    EF1a
    Tags
    None
    Available since
    May 5, 2021
    Availability
    Academic Institutions and Nonprofits only

  8. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV1)

    Viral Prep
    #26966-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.
    Promoter
    EF1a
    Tags
    EYFP (Cre-dependent)
    Available since
    Feb. 14, 2018
    Availability
    Academic Institutions and Nonprofits only

  9. pAAV-Ef1a-Con/Foff 2.0-oScarlet (AAV8)

    Viral Prep
    #137137-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-oScarlet (#137137). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-oScarlet plasmid DNA. EF1a-driven, Cre-dependent expression of oScarlet (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth, INTRSECT 2.0 Project
    Article
    Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)
    Promoter
    EF1a
    Tags
    oScarlet (Cre-dependent)
    Available since
    April 8, 2021
    Availability
    Academic Institutions and Nonprofits only

  10. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV9)

    Viral Prep
    #87306-AAV9
    Purpose
    Ready-to-use AAV9 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Li Zhang
    Article
    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.
    Promoter
    EF1a
    Tags
    None
    Available since
    Jan. 26, 2021
    Availability
    Academic Institutions and Nonprofits only

  11. pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (AAV8)

    Viral Prep
    #137120-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (#137120). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Cre recombinase (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth, INTRSECT 2.0 Project
    Article
    Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)
    Promoter
    EF1a
    Tags
    None
    Available since
    Nov. 23, 2020
    Availability
    Academic Institutions and Nonprofits only

  12. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV2)

    Viral Prep
    #87306-AAV2
    Purpose
    Ready-to-use AAV2 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Li Zhang
    Article
    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.
    Promoter
    EF1a
    Tags
    None
    Available since
    Aug. 24, 2020
    Availability
    Academic Institutions and Nonprofits only

  13. pAAV-Ef1a-Con/Foff 2.0-BFP (AAV8)

    Viral Prep
    #137130-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-BFP (#137130). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-BFP plasmid DNA. EF1a-driven, Cre-dependent expression of BFP (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth, INTRSECT 2.0 Project
    Article
    Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)
    Promoter
    EF1a
    Tags
    BFP (Cre-dependent)
    Available since
    March 19, 2021
    Availability
    Academic Institutions and Nonprofits only

  14. pAAV-Ef1a-Con/Foff 2.0-mCherry (AAV8)

    Viral Prep
    #137133-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-mCherry (#137133). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-mCherry plasmid DNA. EF1a-driven, Cre-dependent expression of mCherry (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth, INTRSECT 2.0 Project
    Article
    Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)
    Promoter
    EF1a
    Tags
    mCherry (Cre-dependent)
    Available since
    April 5, 2021
    Availability
    Academic Institutions and Nonprofits only

  15. pAAV-Ef1a-Con/Foff 2.0-EYFP (AAV8)

    Viral Prep
    #137162-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-EYFP (#137162). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-EYFP plasmid DNA. EF1a-driven expression of EYFP in the presence of Cre (inhibited in the presence of Flp). These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth, INTRSECT 2.0 Project
    Article
    Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)
    Promoter
    EF1a
    Tags
    EYFP (Cre-dependent)
    Available since
    Feb. 2, 2021
    Availability
    Academic Institutions and Nonprofits only

  16. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV8)

    Viral Prep
    #87306-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Li Zhang
    Article
    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.
    Promoter
    EF1a
    Tags
    None
    Available since
    Jan. 26, 2021
    Availability
    Academic Institutions and Nonprofits only

  17. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV5)

    Viral Prep
    #87306-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Li Zhang
    Article
    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.
    Promoter
    EF1a
    Tags
    None
    Available since
    July 22, 2020
    Availability
    Academic Institutions and Nonprofits only

  18. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV Retrograde)

    Viral Prep
    #87306-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Li Zhang
    Article
    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.
    Promoter
    EF1a
    Tags
    None
    Available since
    July 22, 2020
    Availability
    Academic Institutions and Nonprofits only

  19. pAAV-Ef1a-fDIO hChR2(H134R)-EYFP (AAV Retrograde)

    Viral Prep
    #55639-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO hChR2(H134R)-EYFP (#55639). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO hChR2(H134R)-EYFP plasmid DNA. Ef1a-driven, Flp-dependent expression of ChR2(H134R)-EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:
    Promoter
    EF1a
    Tags
    EYFP
    Available since
    Feb. 7, 2025
    Availability
    Academic Institutions and Nonprofits only

  20. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV Retrograde)

    Viral Prep
    #26966-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.
    Promoter
    EF1a
    Tags
    EYFP (Cre-dependent)
    Available since
    March 27, 2024
    Availability
    Academic Institutions and Nonprofits only
Showing: 101 - 120 of 147 results